

Progress is being made in research related to ovarian cancer!



Ovarian Cancer Research and News



Research related to ovarian cancer treatments and diagnostic tests
is ever evolving and progress is being made!

Whether you're a survivor or someone whose life has been impacted
by ovarian cancer, it's helpful to keep abreast of the latest research and news.

Cancer "Moonshot"

Forbes Magazine published a great article by Dr. Saketh Guntupalli, CU Assistant Professor of Gynecologic Oncology, about the government's "Cancer Moonshot" program to find cures for cancer. We think you'll find his article very enlightening. COCA is proud to have Dr. Gunutupalli as a member of our board of directors.



[Click here to read the Forbes article](#)

OCRF Research Finds Inherited Mutations in 18% with Ovarian Cancer

OCRF grantees Dr. Barbara Norquist and Dr. Elizabeth Swisher were part of a team that recently released a study which investigated the occurrence, and role of, inherited cancer associated genes in a randomly selected population of women diagnosed with ovarian cancer. The OCRF-supported study,

published late last month in JAMA Oncology, found that of the 1,915 patients surveyed, eighteen percent carried a gene mutation known to be associated with ovarian cancer, such as BRCA1 and BRCA2. In addition to the nine gene mutations already identified as being associated with OC they identified two others, namely PALB2 and BARD1.

[Learn more](#)

TapImmune Inc. gets fast track status from FDA for study of its vaccine TPIV 200 to treat recurrent ovarian cancer

TapImmune announced that the Food & Drug Administration (FDA) has granted Fast Track designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer.

TPIV 200 cancer vaccine is under investigation as a maintenance therapy with GM-CSF adjuvant in patients with platinum-sensitive advanced ovarian cancer, who achieved stable disease or partial response following completion of standard of care chemotherapy.

[Read more](#)

The ROCA Test


In December, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) of the University College London released the results of its study to determine if the risk of ovarian cancer algorithm (ROCA), when used yearly in conjunction with the CA-125 blood test, helps screen for ovarian cancer and lower mortality rates among post-menopausal women. The study found that combining ROCA with the CA-125 blood test lowers the mortality rate by 20 percent on average for post-menopausal women within the parameters of the study, which was not found to be statistically significant. More specifically, the test reduces mortality at a rate of 8 percent during years 0-7 of having ROCA run annually and 28 percent during years 7-14.

[Learn more](#)

\$2.3M grant to advance OC testing

Baltimore's PapGene Inc. has been awarded a federal grant worth up to \$2.3 million to put toward further development of its ovarian cancer test.

[Read more about it!](#)



Ovarian Cancer Research Fund Alliance Annual Conference

April 1st is the deadline to apply for a

scholarship to the Ovarian Cancer Research Fund Alliance (formerly the Ovarian Cancer National Alliance) Conference in Washington DC happening July 8-11, 2016.

Click below for

[Conference Scholarship Information](#)

Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. In January 2016, they joined together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families.



Conference is inspiring and totally stimulating. Great program and brilliant presenters. Bringing the joy of life to all



Great speakers, upbeat tone, current info from top experts! **Lots of Teal Power & Fun.** This first timer is inspired and ready for 2016 in DC.



Amazing!! **It is so wonderful to meet other strong and amazing women** who have given myself a positive outlook for my journey with cancer. **Survivors!**

Colorado Ovarian Cancer Alliance

NEW ADDRESS: 1777 S. Bellaire St., Suite 170, Denver, CO 80222

303-506-7014

www.Colo-OvarianCancer.org

STAY CONNECTED

